comparison of two blood clotting drugs

Comparison of Topical Tranexamic Acid and Aminocaproic Acid for Total Knee Replacement: A Randomized Trial in Simultaneous Bilateral Total Knee Arthroplasty

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027667

Enrollment

200

Registered

2020-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee Health Condition 2: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: tranexamic acid: tranexamic acid (5 g/100mL of saline mixture)is applied locally over the wound only once after knee replacement to stop bleeding Control Intervention1: aminocaproic aci

Eligibility

Inclusion criteria

Inclusion criteria: Eligible for this study were patients who were undergoing a primary elective bilateral total knee arthroplasty for a diagnosis of osteoarthritis

Exclusion criteria

Exclusion criteria: Patients were excluded for any of the following: (1) an allergy to Tranexamic acid ; (2)preoperative hepatic or renal dysfunction; (3) serious cardiac or respiratory disease, including coronary artery stent placement; (4) congenital or acquired coagulopathy, as evidenced by an international normalized ratio (INR) of >1.4 or a partial thromboplastin time (PTT) of >1.4 times normal; (5)thrombocytopenia, as identified by a preoperative platelet count of autologous blood; (10) diagnosis of inflammatory arthritis; (11) an age of 100 years; and/or (12) a preoperative hemoglobin level of <10 g/dL.

Design outcomes

Primary

Measure	Time frame
The primary outcome measures were perioperative calculated blood loss, total drain output at 24 hours, and perioperative blood transfusion rate. The calculated blood loss was determined from the difference between the preoperative hemoglobin level and the lowest postoperative hemoglobin level during the hospital stay (or prior to transfusion, if applicable)Timepoint: The primary outcome measures were perioperative calculated blood loss, total drain output at 24 hours, and perioperative blood transfusion rate. The calculated blood loss was determined from the difference between the preoperative hemoglobin level and the lowest postoperative hemoglobin level during the hospital stay (or prior to transfusion, if applicable)	—

Measure

Time frame

The primary outcome measures were perioperative calculated blood loss, total drain output at 24 hours, and perioperative blood transfusion rate. The calculated blood loss was determined from the difference between the preoperative hemoglobin level and the lowest postoperative hemoglobin level during the hospital stay (or prior to transfusion, if applicable)Timepoint: The primary outcome measures were perioperative calculated blood loss, total drain output at 24 hours, and perioperative blood transfusion rate. The calculated blood loss was determined from the difference between the preoperative hemoglobin level and the lowest postoperative hemoglobin level during the hospital stay (or prior to transfusion, if applicable)

—

Secondary

Measure	Time frame
secondary outcomes included an analysis of complications, namely symptomatic VTE, cerebrovascular accident, and arterio-occlusive events (such as myocardial infarction).Timepoint: 24 hours	—

Countries

India

Contacts

Public ContactDeepak Bansal

Ludhiana Mediways

deepakbansal1400@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026